-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Market Sentiment Around Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL)
Market Sentiment Around Loss-Making Anavex Life Sciences Corp. (NASDAQ:AVXL)
We feel now is a pretty good time to analyse Anavex Life Sciences Corp.'s (NASDAQ:AVXL) business as it appears the company may be on the cusp of a considerable accomplishment. Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. On 30 September 2022, the US$886m market-cap company posted a loss of US$48m for its most recent financial year. The most pressing concern for investors is Anavex Life Sciences' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts' expectations for the company.
Check out our latest analysis for Anavex Life Sciences
According to the 3 industry analysts covering Anavex Life Sciences, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$134m in 2025. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 53%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
Given this is a high-level overview, we won't go into details of Anavex Life Sciences' upcoming projects, however, bear in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
Before we wrap up, there's one aspect worth mentioning. Anavex Life Sciences currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
Next Steps:
This article is not intended to be a comprehensive analysis on Anavex Life Sciences, so if you are interested in understanding the company at a deeper level, take a look at Anavex Life Sciences' company page on Simply Wall St. We've also put together a list of pertinent aspects you should further research:
- Historical Track Record: What has Anavex Life Sciences' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Anavex Life Sciences' board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
We feel now is a pretty good time to analyse Anavex Life Sciences Corp.'s (NASDAQ:AVXL) business as it appears the company may be on the cusp of a considerable accomplishment. Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. On 30 September 2022, the US$886m market-cap company posted a loss of US$48m for its most recent financial year. The most pressing concern for investors is Anavex Life Sciences' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts' expectations for the company.
我们觉得现在是分析的好时机 Anavex 生命科学公司's(纳斯达克股票代码:AVXL) 看来公司可能正处于取得重大成就的风口浪尖。Anavex Life Sciences Corp. 是一家临床阶段的生物制药公司,从事治疗中枢神经系统(CNS)疾病的候选药物的开发。2022 年 9 月 30 日,这家市值为 8.86 亿美元的公司公布其最近一个财政年度亏损 4,800 万美元。投资者最关心的问题是Anavex Life Sciences的盈利之路——何时会实现盈亏平衡?下面我们将简要概述行业分析师对公司的期望。
Check out our latest analysis for Anavex Life Sciences
查看我们对 Anavex Life Sciences 的最新分析
According to the 3 industry analysts covering Anavex Life Sciences, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$134m in 2025. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 53%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
根据报道Anavex Life Sciences的3位行业分析师的说法,人们的共识是盈亏平衡已经接近了。他们预计该公司将在2024年出现最终亏损,然后在2025年产生1.34亿美元的正利润。因此,预计该公司将在大约两年后实现盈亏平衡。为了在这一天实现盈亏平衡,公司必须同比增长多少?使用最佳拟合线,我们计算出平均年增长率为53%,这相当乐观!如果业务以较慢的速度增长,则盈利的日期将晚于预期。
Given this is a high-level overview, we won't go into details of Anavex Life Sciences' upcoming projects, however, bear in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
鉴于这是一个高层次的概述,我们不会详细介绍Anavex Life Sciences即将推出的项目,但是,请记住,总的来说,生物技术公司的现金流周期不规律,具体取决于产品开发的阶段。因此,高增长率并非不寻常,尤其是在公司处于投资期时。
Before we wrap up, there's one aspect worth mentioning. Anavex Life Sciences currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.
在我们结束之前,有一个方面值得一提。Anavex Life Sciences目前的资产负债表上没有债务,这对于一家消耗现金的生物技术公司来说是很不寻常的,后者的债务相对于其股本通常很高。这意味着该公司纯粹依靠股权投资运营,没有债务负担。这方面降低了投资亏损公司的风险。
Next Steps:
后续步骤:
This article is not intended to be a comprehensive analysis on Anavex Life Sciences, so if you are interested in understanding the company at a deeper level, take a look at Anavex Life Sciences' company page on Simply Wall St. We've also put together a list of pertinent aspects you should further research:
本文无意对Anavex Life Sciences进行全面分析,因此,如果你有兴趣更深入地了解该公司,请看看 Simply Wall Sciences 上的 Anavex Life Sciences 公司页面。我们还整理了一份你应该进一步研究的相关方面的清单:
- Historical Track Record: What has Anavex Life Sciences' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Anavex Life Sciences' board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 历史记录: Anavex Life Sciences过去的表现如何?详细了解过去的往绩分析,并查看我们分析的免费视觉表现以获得更清晰的清晰度。
- 管理小组: 经验丰富的管理团队掌舵增强了我们对业务的信心——看看谁是Anavex Life Sciences董事会成员以及首席执行官的背景。
- 其他表现优异的股票: 还有其他具有良好往绩的股票前景更好吗?在这里浏览我们的免费这些优质股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用不偏不倚的方法根据历史数据和分析师预测提供评论,我们的文章并非旨在提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧